Citi analyst Joanne Wuensch resumed coverage of Boston Scientific with a Buy rating and $54 price target. Boston Scientific is "not a particularly expensive stock for the consistent high-single-digit revenue delivery" and is still producing earnings growth even in this macro environment, Wuensch tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BSX:
- Boston Scientific Snaps up a Stake in Acotec
- Boston Scientific to acquire majority stake of Acotec Scientific
- Boston Scientific Announces Strategic Investment to Acquire Majority Stake of Acotec Scientific Holdings Limited
- Boston Scientific price target raised to $54 from $48 at Raymond James
- Wolfe Research cuts Edwards Lifesciences to Peer Perform on macro, TAVR maturity
